The global non-invasive prenatal testing market size reached USD 5.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 16.4 Billion by 2034, exhibiting a growth rate (CAGR) of 13.30% during 2026-2034.
Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman's blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother's blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.
The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus.
KEY MARKET SEGMENTATION :
Breakup by Product Type:
Breakup by Test Type:
- Materni 21
- Harmony
- Panaroma
- Verifi
- NIFTY
- Others
Breakup by Technology:
Breakup by Method:
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
- Fetal Cells in Maternal Blood Tests
- Others
Breakup by Application:
- Trisomy
- Microdeletion Syndrome
- Others
Breakup by End-User:
- Hospitals
- Diagnostic Laboratories
- Others
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The report provides a comprehensive analysis of the competitive landscape in the global non-invasive prenatal testing market with detailed profiles of all major companies, including:
- Berry Genomics
- BGI
- CENTOGENE GmbH
- Eurofins LifeCodexx GmbH
- F. Hoffmann-La Roche Ltd
- Igenomix
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- MedGenome
- Myriad Genetics, Inc.
- Natera, Inc.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
- Yourgene Health
Key Questions Answered in This Report
1. What was the size of the global non-invasive prenatal testing market in 2025?
2. What is the expected growth rate of the global non-invasive prenatal testing market during 2026-2034?
3. What are the key factors driving the global non-invasive prenatal testing market?
4. What has been the impact of COVID-19 on the global non-invasive prenatal testing market?
5. What is the breakup of the global non-invasive prenatal testing market based on the product type?
6. What is the breakup of the global non-invasive prenatal testing market based on the test type?
7. What is the breakup of the global non-invasive prenatal testing market based on the technology?
8. What is the breakup of the global non-invasive prenatal testing market based on the method?
9. What is the breakup of the global non-invasive prenatal testing market based on the application?
10. What is the breakup of the global non-invasive prenatal testing market based on the end-user?
11. What are the key regions in the global non-invasive prenatal testing market?
12. Who are the key companies/players in the global non-invasive prenatal testing market?